
Jason T Huse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9307564/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Reports, 2022, 38, 110216.	2.9	32
2	The epigenetic dysfunction underlying malignant glioma pathogenesis. Laboratory Investigation, 2022, 102, 682-690.	1.7	4
3	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of Pathology and Laboratory Medicine, 2022, 146, 547-574.	1.2	25
4	Classification of adultâ€ŧype diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathology, 2022, 32, e13062.	2.1	53
5	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathologica, 2021, 141, 303-321.	3.9	30
6	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	1.0	51
7	RARE-23. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR: A CASE SERIES. Neuro-Oncology, 2021, 23, i45-i45.	0.6	Ο
8	Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nature Communications, 2021, 12, 4228.	5.8	21
9	An international perspective on the management of glioblastoma. Chinese Clinical Oncology, 2021, 10, 40-40.	0.4	Ο
10	Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neuro-Oncology Advances, 2021, 3, vdab079.	0.4	6
11	CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Frontiers in Immunology, 2021, 12, 745893.	2.2	6
12	The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021. Current Neurology and Neuroscience Reports, 2021, 21, 67.	2.0	35
13	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. International Journal of Cancer, 2020, 146, 739-748.	2.3	23
14	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1446-1457.	3.3	13
15	Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. Neuro-Oncology, 2020, 22, 450-456.	0.6	30
16	Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment. Oncogene, 2020, 39, 7253-7264.	2.6	10
17	Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Science Translational Medicine, 2020, 12, .	5.8	170
18	YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell, 2020, 38, 857-871.e7.	7.7	203

10 Multionics profiling of primary lung cancers and distant metastance reveals immunosuppression as a common characteristic of tumor cells with metastance plasticity. Genome Biology, 2020, 21, 27, 11. 8,8 20 Targetting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and distant metastance. 2020, 6, eaaz3221. 14. 21 Molecular markers and targeted therapy in pediatric low-grade glioma. Journal of Neuro-Oncology, 14. 14. 22 Blocking immunosuppressive neutrophils deters pY696-E2H236* driven brain metastases. Science 6.8 23 Uttrasmall Core-Shell Slica Nanoparticles for Production Drug Delivery in a High-Orade Malignant marker states biological specimes. Communications Biology, 2020, 32, 147-155. 2.0 24 Robust detection of oncometabolic aberrations by Hisf*13C heteronuclear single quantum correlation in Interve biological specimes. Communications Biology, 2020, 22, 119-115. 0.6 25 CHIO-6. INTEGRATED MOLECULAR PROFILING REVEALS TARCETABLE MOLECULAR ABNORMALITES SHARED of cellomA VALINDUCTION OF p3-NDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, 119-119. 0.6 26 CBIO-13. G-QUADRUPLEX STABILIZATION TARCETS ATRX-DEFICIENT HIGH-GRADE CLIOMA VALINDUCTION OF p3-NDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, 119-119. 0.6 27 MAMU 14. INTERENA RETWEEN DH1 AND ATRX MULTATIONS GOVERN INNATE IMMULINE RESPONSES IN Neuro-Oncology, 2020, 22, 110-110. 0.6 28 CHIO-03. ATRX DOSI NEUBIOTORS	4	#	Article	IF	CITATIONS
20 cholangiocarchiomas. Science Advances, 2020, 6, eaaz3221. 4.7 21 Molecular markers and targeted therapy in pediatric low-grade glioma. Journal of Neuro-Oncology, 1.4 22 Blocking immuno suppressive neutrophils deters pY696-t2H2A26" driven brain metastases. Science 5.8 23 Uttrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant 5.2 24 Robust detection of oncometabolic aberrations by 1H6C*12H2A6** driven brain metastases. Science 5.8 24 Robust detection of oncometabolic aberrations by 1H6C*132020, 3, 124. 2.0 25 PATHO6. INTEGRATED MOLECULAR PROFILING REVEALS TARCETABLE MOLECULIAR ABNORMALITIES SHARED 0.6 26 CBIO-18. C-QUADRUPLEX STABILIZATION TARCETS ATRX.DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF 0.6 26 CBIO-18. C-QUADRUPLEX STABILIZATION TARCETS ATRX.DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF 0.6 27 INMULT 8. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN 0.6 28 TAMI-62. ANCIOCENESIS INHIBITORS STRONCLY SYNERCIZE WITH THERAPEUTICS TARCETING TUMOR 0.6 29 CBIO-03. ATRX.DEFICIENCY IN CLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE 0.6 20 CBIO-03. ATRX.DEFICIENCY IN CLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE 0	-	19		3.8	36
2020, 150, 5-15. 11 22 Blocking immunosuppressive neutrophils deters pY696-EZH28€"driven brain metastases. Science 5.8 23 Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant. 3.2 24 Bobking immunosuppressive neutrophils deters pY696-EZH28€"driven brain metastases. Science 5.8 24 Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-155. 3.2 25 EXTH06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITES SHARED 0.6 26 CEBO-18. C-QUADRUPLEX STABILIZATION TARGETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF 0.6 26 CEBO-18. C-QUADRUPLEX STABILIZATION TARGETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF 0.6 27 IMMU138. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS COVERN INNATE IMMUNE RESPONSES IN 0.6 28 TAMI-62. ANGIOGENESIS INHIBITORS STRONCLY SYNERCIZE WITH THERAPEUTICS TARGETING TUMOR 0.6 29 CEBO-33. ATRX LOSS IN CLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. 0.6 30 CSIC-09, ATRX DEFICIENCY IN CLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE 0.6 31 Spatial Distance Correlates With Cenetic Distance in Diffuse Gloma. Frontiers in Oncology, 2019, 9, 676. 1.3 32 <td< td=""><td>:</td><td>20</td><td></td><td>4.7</td><td>67</td></td<>	:	20		4.7	67
22 Translational Medicine, 2020, 12, 5.3 23 Ultrasmall Core-Shell Silkca Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-158. 3.2 24 Robust detection of oncometabolic aberrations by JH&C*13C heteronuclear single quantum correlation in intact biological specimens. Communications Biology, 2020, 3, 328. 2.0 25 EXTH-06. INTEGRATED MOLECULAR PROFILING REVEAUS TARCETABLE MOLECULAR ABNORMALITIES SHARED O.6 0.6 26 CBIO-18. C-QUADRUPLEX STABILIZATION TARCETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF p53-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, 119-113. 0.6 27 CHUMAS. Neuro-Oncology, 2020, 22, 110-113. 0.6 28 CARCOSS MULTIPLEX STABILIZATION TARCETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF p53-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, 119-113. 0.6 29 CHUMAS. Neuro-Oncology, 2020, 22, 110-0113. 0.6 0.6 29 CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGIZE WITH THERAPEUTICS TARGETING TUMOR Neuro-Oncology, 2020, 22, 11227-11227. 0.6 30 CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE Neuro-Oncology, 2020, 22, 1129-1129. 0.6 31 GPGG. VIRCONNENT IN VICO. Neuro-Oncology, 2020, 22, 1129-1129. 0.6 33 Spatial Distance Correl	:	21		1.4	23
23 Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-158. 342 24 Robust detection of oncometabolic aberrations by 1H46"13C heteronuclear single quantum correlation in intact biological specimens, Communications Biology, 2020, 3, 328. 2.0 25 EXTH-06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. Neuro-Oncology, 2020, 22, II87-II88. 0.6 26 CBIO-18. G-QUADRUPLEX STABILIZATION TARGETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF p53-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, II19-II19. 0.6 27 IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUINE RESPONSES IN GLIOMAS. Neuro-Oncology, 2020, 22, II109-II108. 0.6 28 TAMI-62. ANGIOCENESIS INHIBITORS STRONGLY SYNERCIZE WITH THERAPEUTICS TARGETING TUMOR METABOLISM. Neuro-Oncology, 2020, 22, II227-II227. 0.6 29 CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. Neuro-Oncology, 2020, 22, II227-II227. 0.6 30 CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE 0.6 31 Spatial Distance Correlates With Genetic Distance In Diffuse Glioma. Frontiers In Oncology, 2019, 9, 1.3 1.3 32 Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion Images Identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.	:	22		5.8	64
24 in intact biological specimens. Communications Biology, 2020, 3, 328. 25 25 EXTH-06. INTEGRATED MOLECULAR PROPILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. Neuro-Oncology, 2020, 22, iIB7-IIB8. 0.6 26 CBIO-18. C-QUADRUPLEX STABILIZATION TARGETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF p53-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, iI19-II19. 0.6 27 IMMLI-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS. Neuro-Oncology, 2020, 22, II10-II108. 0.6 28 TAMI-62. ANGIOGENESIS INHIBITORS STRONGLY SYNERGIZE WITH THERAPEUTICS TARGETING TUMOR GLIOMAS. Neuro-Oncology, 2020, 22, II1027-II227. 0.6 29 CBIO-03. ATRX LOSS IN CLIOMA RESULTS IN EPICENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. Neuro-Oncology, 2020, 22, II16-II16. 0.6 30 CSIC-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO. Neuro-Oncology, 2020, 22, II29-II29. 0.6 31 Spatial Distance Correlates With Cenetic Distance in Diffuse Clioma. Frontiers in Oncology, 2019, 9, 676. 1.3 32 Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170. 5.8 33 The medical necessity of advanced molecular testing in the diagnosis and treatiment of brain tumor patients. Neuro-Oncol	:	23	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-158.	3.2	59
25 ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. Neuro-Oncology, 2020, 22, 1187-1188. 0.6 26 CBIO-18. C-QUADRUPLEX STABILIZATION TARGETS ATRX-DEFICIENT HIGH-GRADE GLIOMA VIA INDUCTION OF p53-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, 1119-119. 0.6 27 IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS. Neuro-Oncology, 2020, 22, 1108-1108. 0.6 28 TAMI-62. ANGIOCENESIS INHIBITORS STRONCLY SYNERGIZE WITH THERAPEUTICS TARGETING TUMOR METABOLISM. Neuro-Oncology, 2020, 22, 11227-11227. 0.6 29 CBIO-03. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. Neuro-Oncology, 2020, 22, 1116-1116. 0.6 30 CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO. Neuro-Oncology, 2020, 22, 1129-1129. 0.6 31 Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676. 1.3 32 Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170. 5.8 33 The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508. 0.6 34 Human Messenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Onc	:	24	Robust detection of oncometabolic aberrations by 1H–13C heteronuclear single quantum correlation in intact biological specimens. Communications Biology, 2020, 3, 328.	2.0	3
26 p53-INDEPENDENT APOPTOSIS. Neuro-Oncology, 2020, 22, ii19-ii19. 0.6 27 IMMUL18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS COVERN INNATE IMMUNE RESPONSES IN 0.6 28 TAMI-62. ANCIOCENESIS INHIBITORS STRONGLY SYNERGIZE WITH THERAPEUTICS TARGETING TUMOR 0.6 29 CBIO-03. ATRX LOSS IN CLIOMA RESULTS IN EPICENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. 0.6 30 CSIC-09. ATRX DEFICIENCY IN GLIOMA RESULTS IN EPICENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. 0.6 31 Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676. 1.3 32 Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170. 5.8 33 The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508. 0.6 34 Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360. 2.1 35 Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374. 1.4	:	25		0.6	0
27GLIOMAS. Neuro-Oncology, 2020, 22, ii108-ii108.0.628TAMI-62, ANGIOGENESIS INHIBITORS STRONGLY SYNERGIZE WITH THERAPEUTICS TARGETING TUMOR METABOLISM. Neuro-Oncology, 2020, 22, ii227-ii227.0.629CBIO-03, ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. Neuro-Oncology, 2020, 22, ii16-ii16.0.630CSIG-09, ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO. Neuro-Oncology, 2020, 22, ii29-ii29.0.631Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676.1.332Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.5.833The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.1.4	:	26		0.6	0
28METABOLISM. Neuro-Oncology, 2020, 22, ii227-ii227.0.629CBIO-03. ATRX LOSS IN CLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF CELL CYCLE PHASE TRANSITION. Neuro-Oncology, 2020, 22, ii16-ii16.0.630CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO. Neuro-Oncology, 2020, 22, ii29-ii29.0.631Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676.1.332Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.5.833The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.1.4	:	27		0.6	0
29Neuro-Oncology, 2020, 22, ii16-ii16.0.630CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO. Neuro-Oncology, 2020, 22, ii29-ii29.0.631Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676.1.332Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.5.833The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.1.4	:	28		0.6	0
30MICROENVIRONMENT IN VIVO. Neuro-Oncology, 2020, 22, ii29-ii29.0.631Spatial Distance Correlates With Cenetic Distance in Diffuse Glioma. Frontiers in Oncology, 2019, 9, 676.1.332Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.5.833The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.1.4	:	29		0.6	0
31676.1.332Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.5.833The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of 	;	30		0.6	0
32identify pseudoprogression in glioblastoma. Nature Communications, 2019, 10, 3170.5.833The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.1.434EGFR amplification and classical subtype are associated with a poor response to bevacizumab in1.4	;	31		1.3	8
33patients. Neuro-Oncology, 2019, 21, 1498-1508.0.634Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.2.135Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374.1.436EGFR amplification and classical subtype are associated with a poor response to bevacizumab in1.4	;	32		5.8	113
34 to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360. 2.1 35 Effect of health disparities on overall survival of patients with glioblastoma. Journal of Neuro-Oncology, 2019, 142, 365-374. 1.4 86 EGFR amplification and classical subtype are associated with a poor response to bevacizumab in 1.4	;	33		0.6	49
³⁵ Neuro-Oncology, 2019, 142, 365-374. ^{1.4} EGFR amplification and classical subtype are associated with a poor response to bevacizumab in	:	34	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncolmmunology, 2019, 8, e1655360.	2.1	76
 EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 337-345. 	:	35		1.4	9
	:	36	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 337-345.	1.4	30

#	Article	lF	CITATIONS
37	HGG-08. ATRX LOSS IN PEDIATRIC GBM RESULTS IN EPIGENETIC DYSREGULATION OF G2/M CHECKPOINT MAINTENANCE AND SENSITIVITY TO ATM INHIBITION. Neuro-Oncology, 2019, 21, ii88-ii88.	0.6	0
38	Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases. Acta Neuropathologica Communications, 2019, 7, 63.	2.4	11
39	Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clinical and Translational Radiation Oncology, 2019, 15, 46-52.	0.9	9
40	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nature Communications, 2019, 10, 943.	5.8	132
41	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	7.7	231
42	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	13.7	320
43	Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nature Communications, 2018, 9, 1466.	5.8	52
44	<i>FGFR1</i> tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. Journal of Physical Education and Sports Management, 2018, 4, a002378.	0.5	12
45	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications, 2018, 9, 1057.	5.8	66
46	Novel insights into the epigenetics of diffuse glioma. Molecular and Cellular Oncology, 2018, 5, e1472055.	0.3	1
47	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1039-1054.	0.9	105
48	Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. Journal of Neuro-Oncology, 2018, 139, 469-478.	1.4	18
49	Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series. Neuro-Oncology, 2018, 20, 1625-1633.	0.6	12
50	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics, 2018, 50, 62-72.	9.4	137
51	lbrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 2017, 7, 1018-1029.	7.7	302
52	Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results. Human Pathology, 2017, 69, 15-22.	1.1	29
53	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology, 2017, 19, 1047-1057.	0.6	325
54	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26409.	0.8	66

#	Article	IF	CITATIONS
55	Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clinical Cancer Research, 2017, 23, 3109-3119.	3.2	23
56	Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal of Neuroradiology, 2017, 38, 485-491.	1.2	71
57	EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines. Scientific Reports, 2017, 7, 9043.	1.6	27
58	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathologica, 2017, 133, 417-429.	3.9	172
59	<i>ARID1B</i> alterations identify aggressive tumors in neuroblastoma. Oncotarget, 2017, 8, 45943-45950.	0.8	19
60	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 2017, 12, e0178593.	1.1	38
61	IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports, 2016, 6, 27569.	1.6	26
62	The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science, 2016, 352, aad3018.	6.0	477
63	Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell, 2016, 29, 737-750.	7.7	50
64	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
65	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 2016, 18, 557-564.	0.6	432
66	Stereotactic Radiosurgery for Melanoma BrainÂMetastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 92, 368-375.	0.4	334
67	Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma�. Acta Neuropathologica, 2015, 129, 151-153.	3.9	87
68	TERT promoter mutation designates biologically aggressive primary glioblastoma. Neuro-Oncology, 2015, 17, 5-6.	0.6	10
69	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
70	The Emerging Molecular Foundations of Pediatric Brain Tumors. Journal of Child Neurology, 2015, 30, 1838-1850.	0.7	17
71	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. Molecular Cancer Research, 2015, 13, 1003-1008.	1.5	20
72	A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. Cell Reports, 2014, 8, 1677-1685.	2.9	9

#	Article	IF	CITATIONS
73	Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology, 2014, 16, 1186-1195.	0.6	69
74	Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis. Cell, 2014, 156, 1002-1016.	13.5	672
75	The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. Clinical Cancer Research, 2014, 20, 5601-5611.	3.2	53
76	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2014, 20, 5023-5031.	3.2	89
77	CMV and glioma-are we there yet?. Neuro-Oncology, 2014, 16, 1433-1434.	0.6	5
78	Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma. Cancer Cell, 2014, 26, 288-300.	7.7	322
79	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH</i> . Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356
80	Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth. Cell Stem Cell, 2014, 14, 357-369.	5.2	411
81	Evaluation of <scp>H</scp> istone 3 Lysine 27 Trimethylation (<scp>H3K27me3</scp>) and Enhancer of Zest 2 (<scp>EZH</scp> 2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased <scp>H3K27me3</scp> in <scp><i>H3F3A</i> K27M</scp> Mutant Glioblastomas. Brain Pathology, 2013, 23, 558-564.	2.1	195
82	Glioblastoma: Molecular Analysis and Clinical Implications. Annual Review of Medicine, 2013, 64, 59-70.	5.0	81
83	The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opinion on Medical Diagnostics, 2013, 7, 573-587.	1.6	9
84	Multinodular and Vacuolating Neuronal Tumors of the Cerebrum: 10 Cases of a Distinctive Seizureâ€Associated Lesion. Brain Pathology, 2013, 23, 515-524.	2.1	107
85	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	0.8	213
86	IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. Clinical Cancer Research, 2012, 18, 2490-2501.	3.2	127
87	miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis. PLoS ONE, 2012, 7, e33844.	1.1	106
88	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	13.7	1,668
89	Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget, 2012, 3, 1194-1203.	0.8	241
90	Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia, 2011, 59, 1190-1199.	2.5	201

#	Article	IF	CITATIONS
91	The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes and Development, 2009, 23, 1327-1337.	2.7	465